These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26824431)

  • 21. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
    Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
    BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
    Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP
    Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
    Befrits R; Wikman O; Blomquist L; Hjortswang H; Hammarlund P; Bajor A; Klintman D; Blom H
    Scand J Gastroenterol; 2013 Sep; 48(9):1027-32. PubMed ID: 23889159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbonyl stress induced by intravenous iron during haemodialysis.
    Michelis R; Gery R; Sela S; Shurtz-Swirski R; Grinberg N; Snitkovski T; Shasha SM; Kristal B
    Nephrol Dial Transplant; 2003 May; 18(5):924-30. PubMed ID: 12686666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients.
    Wu CJ; Lin HC; Lee KF; Chuang CK; Chen YC; Chen HH
    Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels.
    Honda H; Tanaka K; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
    Blood Purif; 2019; 47 Suppl 2():63-69. PubMed ID: 30943476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron status and benefit of the use of parenteral iron therapy in pre-dialysis Chronic Kidney disease patients.
    Arogundade FA; Soyinka FO; Sanusi AA; Ojo OE; Akinsola A
    Niger Postgrad Med J; 2013 Dec; 20(4):299-304. PubMed ID: 24633272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
    Roberts MA; Huang L; Lee D; MacGinley R; Troster SM; Kent AB; Bansal SS; Macdougall IC; McMahon LP
    BMC Nephrol; 2016 Nov; 17(1):177. PubMed ID: 27852236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S; Belo L; Reis F; Santos-Silva A
    Blood Rev; 2016 Jan; 30(1):65-72. PubMed ID: 26342303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.
    Kuragano T; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Kitamura K; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura I; Nakanishi T
    Kidney Int; 2014 Oct; 86(4):845-54. PubMed ID: 24759150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial of intravenous and oral iron in chronic kidney disease.
    Agarwal R; Kusek JW; Pappas MK
    Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M; Hojs N; Premru V
    Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
    Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
    Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.